Metabolic treatments of migraine.

Abstract:

:Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavorable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and better tolerated, but they are expensive and may not influence brain dysfunctions upstream in the pathophysiological cascade of migraine, including premonitory and aura symptoms. Biochemical and clinical studies suggest that there may be another complimentary treatment strategy, the one that targets the underestimated metabolic facet of migraine pathophysiology.Areas covered: After a brief description of the metabolic abnormalities found in migraine patients, we will review and discuss published data on metabolic treatments of migraine. There is evidence that riboflavin and co-enzyme Q10 are effective for the prevention of migraine and quasi devoid of adverse effects. Response rates are close to those of topiramate, propranolol, and CGRP/CGRPrec mAbs. The evidence is weaker for thioctic acid. Dietary and pharmacological strategies inducing ketosis are novel promising approaches for which preliminary trials with favorable outcomes have been published.Expert opinion: Metabolic treatments of migraine constitute an effective, well-tolerated, inexpensive, and evidence-supported therapeutic option for migraine prophylaxis, and may be considered as first treatment line in many patients, including in children and adolescents.

journal_name

Expert Rev Neurother

authors

Lisicki M,Schoenen J

doi

10.1080/14737175.2020.1729130

subject

Has Abstract

pub_date

2020-03-01 00:00:00

pages

295-302

issue

3

eissn

1473-7175

issn

1744-8360

journal_volume

20

pub_type

杂志文章
  • Anaplastic astrocytomas: biology and treatment.

    abstract::Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms. Currently, the only factors that have been shown to influence prognosis in patients with AA are age and Karnofsky performance status. Attempts have been made to identify biological prognostic factors for response to therapy an...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.8.4.575

    authors: Chamberlain MC,Chowdhary SA,Glantz MJ

    更新日期:2008-04-01 00:00:00

  • Muscle trigger point therapy in tension-type headache.

    abstract::Recent evidence suggests that active trigger points (TrPs) in neck and shoulder muscles contribute to tension-type headache. Active TrPs within the suboccipital, upper trapezius, sternocleidomastoid, temporalis, superior oblique and lateral rectus muscles have been associated with chronic and episodic tension-type hea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.138

    authors: Alonso-Blanco C,de-la-Llave-Rincón AI,Fernández-de-las-Peñas C

    更新日期:2012-03-01 00:00:00

  • Twenty-five years of evolution of standard diagnostic criteria for neurocysticercosis. How have they impacted diagnosis and patient outcomes?

    abstract::Introduction: Neurocysticercosis (NCC) is the most common helminthic infection of the central nervous system and a global public health problem. However, its diagnosis is complicated since histological demonstration of the parasite is often not feasible, clinical manifestations are nonspecific, most neuroimaging findi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1707667

    authors: Del Brutto OH

    更新日期:2020-02-01 00:00:00

  • Evaluating and managing severe headache in the emergency department.

    abstract::Introduction: Headache is the fifth most common reason to visit an emergency department (ED). In most of the cases, headache is benign and has a primary origin, with migraine as the most common diagnosis. Inappropriate use of ED for non-emergency conditions causes overcrowding, unnecessary testing, and increased medic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1863148

    authors: Luciani M,Negro A,Spuntarelli V,Bentivegna E,Martelletti P

    更新日期:2021-01-04 00:00:00

  • Evaluation and management of headache in primary care.

    abstract::Headache disorders are ubiquitous, common, disabling and to a very large extent treatable in primary care. In this review, the important headache disorders are described together with their impact on public health. Suggestions are set out for their optimal management, although many of these are necessarily based more ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.3.425

    authors: Steiner TJ

    更新日期:2004-05-01 00:00:00

  • Interferon-beta1b in multiple sclerosis.

    abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.3.227

    authors: Buttmann M,Rieckmann P

    更新日期:2007-03-01 00:00:00

  • Developing drug strategies for the neuroprotective treatment of acute ischemic stroke.

    abstract::Developing new treatment strategies for acute ischemic stroke in the last twenty years has offered some important successes, but also several failures. Most trials of neuroprotective therapies have been uniformly negative to date. Recent research has reported how excitatory amino acids act as the major excitatory neur...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1101345

    authors: Tuttolomondo A,Pecoraro R,Arnao V,Maugeri R,Iacopino DG,Pinto A

    更新日期:2015-01-01 00:00:00

  • Combination treatments in Alzheimer's disease: risks and benefits.

    abstract::Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.43

    authors: Sobow T

    更新日期:2010-05-01 00:00:00

  • Valdecoxib for the management of chronic and acute pain.

    abstract::Cyclooxygenase-2 specific inhibitors have anti-inflammatory and analgesic properties, and are effective in managing a wide range of chronic and acute painful conditions such as adult rheumatoid arthritis, osteoarthritis, migraine, primary dysmenorrhea and postoperative pain. Valdecoxib, an orally administered cyclooxy...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.1.11

    authors: Joshi GP

    更新日期:2005-01-01 00:00:00

  • Adverse effects in the treatment of Parkinson's disease.

    abstract::Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be manag...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.1.105

    authors: Singer C

    更新日期:2002-01-01 00:00:00

  • Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies.

    abstract:INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194203

    authors: Amanatkar HR,Papagiannopoulos B,Grossberg GT

    更新日期:2017-01-01 00:00:00

  • Brivaracetam efficacy and safety in focal epilepsy.

    abstract::Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1631160

    authors: Makke Y,Abou-Khalil B

    更新日期:2019-10-01 00:00:00

  • Laser interstitial thermal therapy in the management of brain metastasis and radiation necrosis after radiosurgery: An overview.

    abstract::With advances in stereotactic and neuroimaging techniques, various minimally invasive image-guided techniques have gained widespread acceptance in the field of neuro-oncology. Laser interstitial thermal therapy (LITT) is an image-guided technique that involves generation of high temperatures using a laser fiber, to ab...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2016.1135736

    authors: Sharma M,Balasubramanian S,Silva D,Barnett GH,Mohammadi AM

    更新日期:2016-01-01 00:00:00

  • Current concept of anxiety: implications from Darwin to the DSM-V for the diagnosis of generalized anxiety disorder.

    abstract::This article proposes a revision of the historical evolution of the concepts of generalized anxiety disorder (GAD). Currently, Darwin's evolutionary theory is the hegemonic paradigm for modern science and influences research on mental disorders. Throughout the 20th Century, the editions of the Diagnostic and Statistic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.101

    authors: Coutinho FC,Dias GP,do Nascimento Bevilaqua MC,Gardino PF,Pimentel Rangé B,Nardi AE

    更新日期:2010-08-01 00:00:00

  • Microbiota-gut brain axis involvement in neuropsychiatric disorders.

    abstract::Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1638763

    authors: Iannone LF,Preda A,Blottière HM,Clarke G,Albani D,Belcastro V,Carotenuto M,Cattaneo A,Citraro R,Ferraris C,Ronchi F,Luongo G,Santocchi E,Guiducci L,Baldelli P,Iannetti P,Pedersen S,Petretto A,Provasi S,Selmer K,Sp

    更新日期:2019-10-01 00:00:00

  • Epilepsy in the elderly.

    abstract::Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.170

    authors: Johnston A,Smith PE

    更新日期:2010-12-01 00:00:00

  • Chemotherapy for malignant glioma.

    abstract::Malignant gliomas comprise a small percentage of all cancers, but continue to cause disproportionate levels of morbidity and mortality. Despite decades of intensive effort from many disciplines--surgery, radiation oncology and medicine--they remain refractory to cure and, in most cases, even to prolonged treatment res...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.S41

    authors: Nicholas MK,Lukas R,Bangalore S

    更新日期:2005-11-01 00:00:00

  • Cannabinoids as potential new therapy for the treatment of gliomas.

    abstract::Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6-12 months. The development of new the...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.1.37

    authors: Parolaro D,Massi P

    更新日期:2008-01-01 00:00:00

  • Treatments for generalized anxiety disorder.

    abstract::Generalized anxiety disorder is characterized by excessive chronic anxiety in association with many somatic symptoms. The disorder has pervasive effects on quality of life, including work, social and educational aspects and requires long-term therapy. Available studies in patients are the Diagnostic and Statistical Ma...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.2.285

    authors: Struzik L,Vermani M,Coonerty-Femiano A,Katzman MA

    更新日期:2004-03-01 00:00:00

  • Fingolimod for the treatment of relapsing multiple sclerosis.

    abstract::Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of l...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.193

    authors: Jeffery DR,Markowitz CE,Reder AT,Weinstock-Guttman B,Tobias K

    更新日期:2011-02-01 00:00:00

  • Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.

    abstract::Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1848548

    authors: Dorfman BJ,Jimenez-Shahed J

    更新日期:2021-01-01 00:00:00

  • Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.

    abstract:INTRODUCTION:Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neurop...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1340832

    authors: Nobile-Orazio E,Gallia F,Terenghi F,Bianco M

    更新日期:2017-08-01 00:00:00

  • Update on therapies for cluster headache.

    abstract::Cluster headache is one of the primary headache disorders. It is considered the most severe headache syndrome known to humans. In most instances, this disorder is readily treatable when the correct medications are utilized at the correct dosages. Cluster headache treatment involves abortive, transitional and preventiv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.3.295

    authors: Rozen TD

    更新日期:2002-05-01 00:00:00

  • Tension-type headache.

    abstract::Tension-type headache (TTH) is the most prevalent of all headaches and also represents one of the most expensive clinical conditions for the health system. Despite the high impact of this disorder and the existence of well-established diagnostic criteria, knowledge about TTH is still quite limited. In most cases in wh...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.5.839

    authors: Speciali JG,Eckeli AL,Dach F

    更新日期:2008-05-01 00:00:00

  • Barriers to the use of genetic information for the development of new epilepsy treatments.

    abstract::Genetic analysis is providing new information on the biological basis of epilepsy at a rapid pace; this article identifies factors acting as major barriers to use of these data for therapy development. Disease heterogeneity is a primary obstacle since so many genes can cause or predispose to epilepsy and the clinical ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 社论,评审

    doi:10.1586/14737175.2016.1115718

    authors: Ferraro TN

    更新日期:2016-01-01 00:00:00

  • Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

    abstract::Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1028370

    authors: Rizzo R,Martino D

    更新日期:2015-04-01 00:00:00

  • Pseudotumor cerebri presenting as headache.

    abstract::Pseudotumor cerebri (PTC) is characterized by intracranial hypertension without ventriculomegaly, in the absence of a mass lesion or meningeal process. When there is no secondary cause, it is termed 'idiopathic intracranial hypertension'. Headache is the most common symptom of PTC, present in over 90% of patients. The...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.3.397

    authors: Friedman DI

    更新日期:2008-03-01 00:00:00

  • Anaplastic glioma: current treatment and management.

    abstract::Anaplastic glioma (AG) is divided into three morphology-based groups (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) as well as three molecular groups (glioma-CpG island methylation phenotype [G-CIMP] negative, G-CIMP positive non-1p19q codeleted tumors and G-CIMP positive codeleted...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1042455

    authors: Le Rhun E,Taillibert S,Chamberlain MC

    更新日期:2015-06-01 00:00:00

  • Dual tasking in Parkinson's disease: should we train hazardous behavior?

    abstract::Dual-task (DT) circumstances aggravate gait disorders in Parkinson's disease (PD) and are associated with an increased risk of falling and reduced functional mobility. Clinical rehabilitation guidelines for PD consider DT interventions as potentially hazardous and recommend avoiding them in daily life. The current art...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1077116

    authors: Strouwen C,Molenaar EA,Münks L,Keus SH,Bloem BR,Rochester L,Nieuwboer A

    更新日期:2015-01-01 00:00:00

  • Management of von Hippel-Lindau disease-associated CNS lesions.

    abstract::Patients with von Hippel-Lindau disease (VHL) often harbor significant disease burden within the CNS, specifically craniospinal-axis hemangioblastomas and endolymphatic sac tumors (ELSTs). The majority (60-80%) of patients with VHL harbor hemangioblastomas, and 10-15% will develop ELSTs. Advances in the understanding ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.124

    authors: Wind JJ,Lonser RR

    更新日期:2011-10-01 00:00:00